All News

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver disease surges.

Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better outcomes than natural history controls for all measures.

Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

Tocilizumab alone and in combination with methotrexate outperformed the latter drug in patients who did not adequately respond to conventional synthetic disease-modifying antirheumatic drugs.

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin Engelke, MS, offering a potential tool for improving diagnosis worldwide.

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those with higher BSA, a new study finds.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

In this clip, Adela Perolla, MD, PhD, discusses the urgent need to address and destigmatize burnout in hematology, especially among early-career professionals, by promoting self-awareness, work-life balance, and peer support.

The announcement of the new members of the CDC Advisory Committee on Immunization Practice comes days after the HHS secretary removed all previous members of the panel.

Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.

The algorithm and automated workflows significantly cut turnaround times for genomic testing for newly-diagnosed acute myeloid leukemia (AML), enabling faster, more personalized treatment decisions.

Race-free kidney function equations may underestimate risks for Black adults according to a new analysis.

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.

Those who developed primary open-angle glaucoma (POAG) had lower mental health scores compared with those who had not developed the condition.

Treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) showed promising results in a midstage clinical trial, significantly improving key measures of heart and lung function.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling earlier intervention and improving patient outcomes.

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Sodium reduction is key to lowering blood pressure in adults with type 2 diabetes, a study finds.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not require biomarker testing.